A new, evidenced-based clinical practice guideline on molecular biomarker testing for patients with colorectal cancer identifies opportunities for improving patient outcomes. This pivotal guideline ...
MUSCAT: The Royal Hospital succeeded in localising molecular tests for colorectal cancer (KRAS, NRAS, BRAF) as part of ...
Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...
Data support routine use of circulating tumor DNA testing in management of stage III colon cancer patients Tumor fraction analysis provides further insights for patient management in patients with ...
Results from prospective molecular residual disease (MRD) study show a positive Oncodetect test result is strongly associated with recurrence in stage III colon cancer patients Oncodetect test ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare ...
For 10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback